Product Images Dronabinol

This is a description of a prescription drug called Dronabinol available in capsule form. The capsules contain 10 mg of Dronabinol, and the usual dosage is provided in the package insert. The drug should be stored in cool temperatures, and a broken or missing seal indicates that the product should not be used. The drug is manufactured by Ascent Pharmaceuticals and distributed by Camber Pharmaceuticals.*

This is a medication description for Dronabinol capsules, which contain 2.5mg of Dronabinol, USP. The usual dosage is mentioned and storage instructions advise keeping the capsules in a well-closed container in a cool environment between 2°C to 8°C. The manufacturer for the capsules is Camber Pharmaceuticals, Inc., located in Piscataway, NJ, and the capsules are manufactured by Ascent Pharmaceuticals, Inc., located in Central Islip, NY.*

Each capsule of CAMKBE Dronabinol USP contains 5mg. The usual dosage information can be found in the package insert. The capsules should be stored in a well-closed container in a cool environment, between 2° to 8°C (36° to 46°F) or in a refrigerator to protect from freezing. If the seal over the bottle opening is broken or missing, do not accept. Camber Pharmaceuticals, Inc. has manufactured it and Ascent Pharmaceuticals, Inc. has produced it. Rxonly, and 60 capsules are provided.*

This is a summary of the pharmacokinetic parameters of Dronabinol in healthy subjects under fasted conditions. It includes the mean and standard deviation values for plasma concentration, time to maximum concentration, and area under the plasma concentration-time curve for three different twice-daily doses (5mg, 10mg, and 25mg). The maximum observed plasma concentration, time to maximum observed plasma concentration, and area under the plasma concentration-time curve from 0 to 12 hours are also listed.*

This looks like the results of a clinical trial comparing the effect of Dronabinol (2.5 mg taken twice a day) vs. Placebo on appetite change from baseline. The measurement used is likely the mm VAS scale, with the mean change in appetite reported over a period of several weeks. The *p-value<005 suggests that there was a statistically significant difference between the treatment and placebo groups.*

This appears to be a list of symptoms that could be associated with various medical conditions. It is important to note that these symptoms are not specific to any particular illness and may be indicative of a range of disorders. It is recommended that individuals experiencing any of these symptoms consult with a healthcare professional for proper diagnosis and treatment.*

This is a description of common and less frequent adverse reactions observed in clinical trials. The text lists various adverse reactions for different system organ classes, such as asthenia, palpitations, abdominal pain, nausea, vomiting, dizziness, euphoria, confusion, hallucination, and more. The actual incidence of some adverse reactions is noted to be between 3% to 10%. Additionally, less common reactions were observed, such as malaise, anorexia, hepatic enzyme elevation, myalgias, speech difficulties, cough, sinusitis, flushing, and vision difficulties. However, it is worth noting that this text is incomplete and has typos.*